Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and another hormone, appears to represent a significant advancement for body loss . Preliminary clinical investigations have shown substantial reductions in visceral fat , possibly surpassing existing obesity treatments. However , more study is needed to thoroug